Press releases
- Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
- Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
- Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
- Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
- Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
- Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
- Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
- Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
- Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
- Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
More ▼
Key statistics
On Friday, Akeso Inc (4RY:MUN) closed at 4.88, -19.34% below its 52-week high of 6.05, set on Mar 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.88 |
---|---|
High | 4.88 |
Low | 4.88 |
Bid | 4.74 |
Offer | 4.84 |
Previous close | 4.88 |
Average volume | 5.46k |
---|---|
Shares outstanding | 865.86m |
Free float | 634.96m |
P/E (TTM) | 16.90 |
Market cap | 38.27bn HKD |
EPS (TTM) | 2.62 HKD |
Data delayed at least 15 minutes, as of Jun 07 2024 07:10 BST.
More ▼